Frontiers
US$ 26.34
gip/glp-1 receptor agonist drugs GIPR/GLP-1R dual therapies for diabetes and weight loss—chemistry, physiology, and clinical applications Frontiers | Clinical perspectives on
Description
The list of conditions for which GLP-1 drugs provides benefit independent of weight loss keeps growing
Learn key deadlines, compliance, and alternatives.
The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing weight management strategies.
Understand combinations, interactions, and when alternatives may fit better.
The GLP-1 receptor assay is a powerful tool for the identification of GLP-1 receptor agonists aimed at treating obesity and type 2 diabetes
